A new article published in the American Journal of Obstetrics and Gynecology compared contraceptive methods used among human immunodeficiency virus (HIV)-infected and non-infected women, availing private insurance in the United States; and evaluated the association between antiretroviral therapy use and contraceptive method use. In this study, United States nationwide healthcare claims database was used to identify women between the age of 15 and 44 years having coverage for prescription drugs. The prevalence of contraceptive use by HIV infection status and by use of antiretroviral therapy, among those with HIV, were calculated. It was observed that although contraceptive use increased among HIV-infected and non-infected women from 2008 to 2014; a lower proportion of HIV-infected women used prescription contraceptive methods, during this period. Additionally, HIV-infected women had lower odds of using long-acting reversible contraception or short-acting hormonal contraception methods, when compared to HIV non-infected women. In 2014, HIV-infected women on antiretroviral therapy were significantly more likely to use no method for contraception, and significantly less likely to use short-acting hormonal contraception, when compared to those without antiretroviral therapy. Whereas no significant difference was found in female sterilization, by HIV status or antiretroviral therapy use. Hence, it was stated that despite the safety of reversible contraceptives for women with HIV, the use of prescription contraception continues to be lower among privately-insured HIV-infected women compared to non-infected women, especially among those receiving antiretroviral therapy.